2022-04-19 Cell Research Tian Changlin's research group reveals the structural basis for the activation of thyrotropin-releasing receptor by endogenous peptides and oral peptide drugs in the HPT
Time of Update: 2022-05-20
Figure 2 : TRHR/miniGq complex binds to the agonist TRH (prorelin) or TAL (tatirelin) electron microscope structure TAL has a lower affinity for TRHR than TRH , but the effect is stronger than TRHCompared with the hydrophilic first residue pyro-Glu in TRH , the first residue of TAL is replaced by a nitrogen-containing heterocycle with highly hydrophobic properties, which is the main reason for the strong hydrophobicity and oral properties of TAL .
Xianweida Announces Initiation of Patient Dosing in the International Multicenter IIb Clinical Trial of Its GLP-1 Drug Candidate XW003 in Obesity
Time of Update: 2022-02-17
, a clinical-stage biotechnology company focused on researching and developing innovative treatments for chronic metabolic diseases, announced today that the Phase IIb clinical trial of XW003 for the treatment of obesity has initiated patient dosing .
Beijing Shuangju Pharmaceutical Lilaglutide injection was approved clinically
Time of Update: 2020-10-15
At present, only the original Yanno and Nord's Lilaglutide injections were approved for sale, with different classifications and different processes to express the system of declaration of enterprises approved clinical has Tonghua Dongbao, Shenzhen Hanyu, Chengdu Sanno, Zhuhai Federal Pharmaceuticals and other eight.
"Pharmaceutical Express" Baiotai Hong Kong Stock Exchange IPO application to accept the first PrEP drug approved in China
Time of Update: 2020-09-11
(Sina Pharmaceutical News) First-line treatment of gastric/esophageal cancer BMS immunocommunication therapy reaches phase 3 clinical endpoint BMS announced, a project called CheckMate-649, designed to evaluate Odivo combined chemotherapy compared to alone chemotherapy Key Phase 3 clinical studies for the first-line therapeutic effect of metastatic gastric cancer, gastroesophageal connecting cancer or esophageal adenocarcinoma patients with PD-L1 expression-positive, i.e. combined positive score of 5, reached the total survival and non-progressive survival of the main study endpoint.
FDA accepts listing application for oberic acid treatment for non-alcoholic fatty hepatitis
Time of Update: 2020-06-07
recently, Intercept announced The FDA (http:// has accepted a market ingressation application for the treatment of non-alcoholic fatty hepatitis (NASH) for liver fibrosis and has been qualified f
Blockbuster innovative drugs debut at the global clinical data release of China Pharmaceutical Innovation and Investment Conference
Time of Update: 2016-11-14
Source: China Council for the promotion of drugs November 14, 2016 Japan China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as the conference) opened ceremoniously Seve